We advise to exercise US Stem Cell fundamental analysis to find out if markets are at this time mispricing the firm. Strictly speaking this technique allows you to confirm available fundamental indicators of US Stem Cell as well as the relationship between them. We were able to interpolate data for twenty-eight available financial indicators for US Stem, which can be compared to its peers in the sector. The stock experiences a normal downward fluctuation but is a risky buy. Check odds of US Stem to be traded at $1.0E-4 in 90 days.
USRM
US Stem Stock Summary
US Stem competes with Gilead Sciences, Sanofi ADR, Amgen, Merck, and Novo Nordisk. Stem Cell, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of autologous cellular therapies for the treatment of chronic and acute heart damage, and vascular and autoimmune diseases in the United States. Stem Cell, Inc. was incorporated in 1999 and is headquartered in Sunrise, Florida. US Stem operates under Biotechnology classification in the United States and is traded on OTC Exchange.
There are many critical financial ratios that US Stem's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that US Stem Cell reports annually and quarterly.
Comparative valuation techniques use various fundamental indicators to help in determining US Stem's current stock value. Our valuation model uses many indicators to compare US Stem value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across US Stem competition to find correlations between indicators driving US Stem's intrinsic value. More Info.
US Stem Cell is rated below average in return on asset category among its peers. It also is rated below average in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the US Stem's earnings, one of the primary drivers of an investment's value.
Other Information on Investing in USRM Pink Sheet
US Stem financial ratios help investors to determine whether USRM Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in USRM with respect to the benefits of owning US Stem security.